Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1181-1188

  Gupta, Anshu ^a,b   Miki, Kenji ^c   Xu, Mingxu ^a   Yamamoto, Norio ^a,b,d   Moossa, A R ^b   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Doxorubicin; Gene therapy; MET gene; Methioninase; Selenomethione

Indexed keywords

ADENOVIRUS METHIONINASE; DOXORUBICIN; SELENOMETHIONINE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL PROTEINS; BIOTRANSFORMATION; CARBON-SULFUR LYASES; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GENES, SYNTHETIC; GENETIC VECTORS; INJECTIONS, INTRADERMAL; LUNG NEOPLASMS; MALE; MASTADENOVIRUS; MICE; MICE, NUDE; PRODRUGS; PROMOTER REGIONS (GENETICS); PSEUDOMONAS PUTIDA; RECOMBINANT FUSION PROTEINS; SELENOMETHIONINE; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038239205     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR and Hoffman RM: Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Research 61: 6805-6810, 2001.
2. Esaki N, Tanaka H, Uemura S, Suzuki T and Soda K: Catalytic action of L-methionine γ-lyase on selenomethionine and selenols. Biochemistry 18: 407-410, 1979.
3. Chaudiere J, Courtin O and Leclaire J: Glutathione oxidase activity of selenocystamine: A mechanistic study. Arch Biochem Biophys 296: 328-336, 1992.
4. Yan L and Spallholz E: Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem Pharmacol 45: 429-437, 1993.
5. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
6. Cai J, Yang J and Jones DP: Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1366: 139-149, 1998.
7. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
8. Thomberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
9. Spallholz JE: On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 17: 45-64, 1994.
10. Stewart MS, Spallholz JE, Nelder KH and Pence BC: Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med 26: 42-48, 1999.
11. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM and Sugita K: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 58: 2583-2587, 1998.
12. Tan Y, Sun X, Xu M, Tan XZ, Sasson A, Rashidi B, Han Q, Tan XY, Wang X, An Z, Sun FX and Hoffman RM: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clinical Cancer Res 5: 2157-2163, 1999.
13. Miki K, Xu M, An Z, Wang X, Yang M, Al-Refaie W, Sun X, Baranov E, Tan Y, Chishima T, Shimada H, Moossa AR and Hoffman RM: Survival efficacy of the combination of methioninase gene and methioninase in a lung cancer orthotopic model. Cancer Gene Therapy 7: 332-338, 2000.
14. Miki K, Al-Refaie W, Xu M, Jiang P, Tan Y, Bouvet M, Zhao M, Gupta A, Chishima T, Shimada H, Makuuchi M, Moossa AR and Hoffman RM: Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Cancer Res 60: 2696-2702, 2000.
15. Hoffman RM and Erbe RW: High in vivo rate of methionine biosynthesis in transformed human and malignant rat cells auxotropic for methionine. Proc Nail Acad Sci USA 73: 1523-1527, 1976.
16. Mecham JO, Rowitch D, Wallace CD, Stern PH and Hoffman RM: The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117: 429-434, 1983.
17. Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis: a review and synthesis. Biochim Biophys Acta 738: 49-87, 1984.
18. Stern PH, Wallace CD and Hoffman RM: Altered methione metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119: 29-34, 1984.
19. Stern PH, Mecham JO, Wallace CD and Hoffman RM: Reduced free-methionine in methionlne-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 117: 9-14, 1983.
20. Breillout F, Antoine E and Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82: 1628-1632, 1990.
21. Chabner BA and Collins JM: Cancer Chemotherapy: Principles and Practice. Philadelphia, Lippincott, 1990.
22. Muindi J, Sinha BK, Gianni L and Myers C: Thiol dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. Mol Pharmacol 27: 356-365, 1985.
23. May PM, Williams GR and Williams DR: Solution chemistry studies of adriamycin-iron complexes present in vivo. Eur J Cancer 16: 1275-1276, 1980.
24. Feigon J, Denny WA, Leupin W and Kearns DR: Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics. J Med Chem 27(4): 450-465, 1984.
25. Collier DA, Neidle S and Brown JR: Molecular models for the interaction of the anti-turnout drug nogalamycin with DNA. Biochem Pharmacol 33(18): 2877-2880, 1984.
26. Bachur NR, Gee MV and Friedman RD: Nuclear catalyzed antibiotic free radical formation. Cancer Res 42: 1078-1081, 1982.
27. 2 consumption and free radicals formation. Res Commun Chem Pathol Pharmacol 44: 445-459, 1984.
28. Dodd NJ and Mukherjee T: Free radical formation from anthracyclin antitumor agents and model systems - I. Model naphthoquinones and anthraquinones. Biochem Pharmacol 33: 379-385, 1984.
29. Burton KP, McCord JM and Ghai G: Myocardial alterations due to free-radical generation. Am J Physiol 246: H776-783, 1984.
30. Yang M, Hasegawa S, Jiang P, Wang X, Tan Y, Chishima T, Shimada H, Moossa AR and Hoffman RM: Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Res 58: 4217-4221, 1998.